Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported its third quarter financial results, revealing a net loss of $12.8 million, or $0.47 per share, compared to a loss of $10.5 million, or $0.42 per share, in Q3 2020. The company has received satisfactory resolution on deficiencies at a contract manufacturing organization from the FDA, allowing them to proceed with the approval process for VP-102, targeting molluscum contagiosum. Additionally, Verrica is advancing LTX-315 for basal cell carcinoma, submitting an IND, and expects to start a Phase 2 trial in early 2022.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced on September 20, 2021, that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for VP-102, aimed at treating molluscum contagiosum. While the FDA identified general quality deficiencies at the contract manufacturing organization, no specific manufacturing or clinical issues were cited for VP-102. The company remains optimistic about resolving these concerns within 30 business days, highlighting a significant unmet need for an FDA-approved treatment for the six million people affected in the U.S.
Verrica Pharmaceuticals announced its Q2 2021 financial results, showing a net loss of $11.8 million, or $0.43 per share. This reflects a wider loss compared to $9.4 million in Q2 2020. The company recognized $12 million in license revenues from its agreement with Torii Pharmaceutical, with total cash and marketable securities at $90.1 million as of June 30, 2021. Verrica is preparing for a potential launch of its lead product candidate, VP-102, aimed at molluscum contagiosum, with a PDUFA goal date set for September 23, 2021, while also expanding its commercial operations.
Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Terry Kohler as Chief Financial Officer to enhance its management team in light of the potential commercial launch of VP-102, a treatment for skin diseases. Kohler brings over 20 years of experience, most recently from a global pharmaceutical company with annual revenues exceeding $2 billion. He succeeds Brian Davis, who is leaving the company. This leadership change aims to bolster commercial preparations for the expected launch this fall, as stated by CEO Ted White.
Verrica Pharmaceuticals has announced a three-month extension of the PDUFA goal date for its New Drug Application (NDA) for VP-102, now set for September 23, 2021. This extension allows the FDA additional time to review information on Verrica's training program and distribution model, following comments on a human factors study. Despite the delay, Verrica remains confident in VP-102 as a treatment for molluscum contagiosum, especially after the FDA completed one of two required pre-approval inspections. VP-102 could become the first FDA-approved treatment for this common skin condition affecting six million U.S. children.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. The event can be accessed via a live webcast. Verrica specializes in dermatology therapeutics, with a focus on late-stage product candidates like VP-102 for treating molluscum, common warts, and external genital warts. Additionally, they are developing VP-103 for plantar warts and have a global licensing agreement with Lytix Biopharma to develop LTX-315 for dermatologic oncology conditions.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Ted White will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. ET. The presentation will include insights into Verrica's dermatology therapeutics, especially their late-stage product candidates, VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has a global license agreement with Lytix Biopharma for developing LTX-315 for dermatologic oncology.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported its first-quarter financial results for 2021, highlighting a significant expansion and preparation for the potential FDA approval of VP-102 for molluscum, with a PDUFA goal date set for June 23, 2021. The company raised $30 million through a public offering and recognized $12 million in license revenues from its agreement with Torii Pharmaceutical for VP-102's development in Japan. The net loss narrowed to $0.9 million from $9.8 million year-over-year, with cash equivalents of $87.7 million supporting operations through mid-2023.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 8:45 a.m. ET. CEO Ted White will lead the presentation, which highlights Verrica's focus on dermatology therapeutics. The company is advancing VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology. A live webcast and replay will be available for those unable to attend the event.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that Dr. Gary Goldenberg has been elected as an active member of the American Dermatological Association (ADA), a prestigious recognition in dermatology. CEO Ted White praised Dr. Goldenberg for his contributions to the field. The ADA, founded in 1876, aims to improve dermatologic health care and is known for its influential role in dermatological education and research. Verrica focuses on developing treatments for skin diseases, including its late-stage candidate VP-102 for molluscum and warts, and has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology.